FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Robert Spomer has joined the company as Senior Vice President of Sales.
“Robert significantly bolsters Moximed’s commercial leadership,” said Chris Gleason, President and CEO of Moximed. “He’s successfully built and led sales teams whose introduction of disruptive technologies transformed the standard of care in numerous medical fields. Moximed is rapidly investing in and expanding its commercial infrastructure, and Robert’s leadership and ability to deploy a winning formula with proven results will be instrumental as we accelerate adoption of the MISHA® Knee System.”
Prior to joining Moximed, Spomer served as the Vice President of Sales at Intrinsic Therapeutics. Spomer previously held sales leadership roles at multiple disruptive medical technology companies, including: Stryker, Acclarent (acquired by JNJ), Spirox (acquired by Entellus), and Neotract (acquired by Teleflex).
“I am thrilled to join Moximed and help fuel the growth of the business,” said Mr. Spomer. “The MISHA Knee System has the potential to help millions of symptomatic knee OA patients regain the active and fulfilling life they deserve. The product has generated enthusiastic surgeon and patient interest, and I look forward to our team helping surgeons offer this treatment option for their patients."
Spomer’s hire is a key role in a rapidly expanding commercial team as Moximed scales to meet increasing surgeon demand for the MISHA Knee System. Along with Spomer, recent additions include sales, reimbursement, and sales support roles as the commercial infrastructure is built out. Moximed is on pace to double full-time headcount this year.
About The MISHA® Knee System
Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.
Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.
Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.
The MISHA Knee System is FDA cleared.
About Moximed
Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.
To learn more, visit www.moximed.com.
